ZURICH (Reuters) – Swiss drugmaker Roche raised its 2019 outlook after first-quarter sales beat analyst forecasts on the strength of newer medicines including multiple sclerosis treatment Ocrevus and cancer immunotherapy Tecentriq.
Roche said sales are now expected to grow in the mid-single digit range, at constant exchange rates.
Revenue in the first quarter rose to 14.8 billion Swiss francs ($14.70 billion), compared to the 14.2 billion franc average forecast in a poll for Reuters. Ocrevus sales rose 67 percent to 836 million francs. Tecentriq revenue more than doubled to 336 million francs.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.